Malignant Mesothelioma Market

Malignant Mesothelioma Market Outlook (2024 to 2034)

The global malignant mesothelioma market size is estimated to be valued at US$ 561.9 million in 2024. The market is projected to register a promising CAGR of 7.6% to accumulate sales worth US$ 1,164.9 million by 2034.

Key players providing malignant mesothelioma therapeutics are expected to deploy tools like artificial intelligence, 3D printing, and nanotechnology for improved production efficiency. Thereby meeting the increasing demand for drugs/ medications to raise the patient's life expectancy.

Leading companies are also taking significant steps to develop novel products that offer improved efficacy and results. Thus increasing their reliability and preference among healthcare practitioners.

Factors Uplifting the Growth of Malignant Mesothelioma Market

Surging consumption habits related to tobacco and cigarettes, to reduce stress levels or for other purposes, have been observed as a primary factor behind increasing cases of malignant mesothelioma. People are becoming concerned for their health as the prevalence of malignant mesothelioma continues to escalate. Out of worry, people are taking precautions and diagnosis for early disease detection. Moreover, rising approvals for effective combined therapy are expected to favor malignant mesothelioma therapeutics.

Numerous active players are working in association with other organizations to discover the effects of combining several medications on malignant mesothelioma. Further, various firms are executing clinical studies concentrating on different combination medications owing to a lack of technique patents.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 561.9 million
Forecasted Market Value (2034F)	US$ 1,164.9 million
Projected Growth Rate (2024 to 2034)	7.6%CAGR
Pemetrexed and Combination Segment Growth Rate (2024 to 2034)	7.8% CAGR
Parental Segment Growth Rate (2024 to 2034)	7.6% CAGR
North America Market Share (2024)	37%
Latin America Market Share (2024)	11.9%
Key Companies Profiled in the Malignant Mesothelioma Industry Report	Merck KGaA Novartis AG Beckman Coulter Inc. bioMerieux Bio-Rad Laboratories, Inc Danaher Hologic Gilead Sciences, Inc. Emcure Pharmaceuticals Limited. (India) Cipla Inc. Hetero Bausch Health Companies Inc. Johnson & Johnson Private Limited Mylan N.V. Sun Pharmaceutical Industries Limited AstraZeneca Sanofi S.A. Arena Pharmaceuticals, Inc. ONO PHARMACEUTICAL CO., LTD Others

Which Trends Dictate the Malignant Mesothelioma Market?

“Increasing Research and Development Activities is Enhancing the Market Scope of Malignant Mesothelioma”

Leading firms are extensively investing in research and development activities to launch targeted therapies that focus on particular molecules or pathways engaged in the development and proliferation of cancer cells. Consequently, developing a positive outlook for malignant mesothelioma therapeutics. The launch of high-resolution CT scanning to detect abnormalities in certain body parts is also giving momentum to market expansion.

What are the Main Challenges that are Restricting the Market’s Growth?

“Unfavorable Aspects of Malignant Mesothelioma Drugs Like High Cost and Low Survival Rate”

Drugs prescribed for the treatment of malignant mesothelioma are heavy on pockets. This restricts its uptake in countries where income levels are average, and prospects for additional expenses are dim. In addition to this, the low survival rate offered by these drugs, which is usually five years or less, is also limiting the consumption of drugs intended for malignant mesothelioma.

Region-wise Insights

Which Region Captures Substantial Market Share in the Following Years?

“North America’s Share in the Market is Prominently High”

As per the recent market estimates, the North America malignant mesothelioma market is expected to acquire a massive value share of 37% in 2024. Revenue generated by this regional market is forecast to rise from US$ 208 million in 2024 to US$ 389 million by 2034. Demand for malignant mesothelioma therapeutics is projected to register a 6.5% CAGR during this period.

Growth in North America is expected to be driven by rising knowledge about drug and diagnostic procedures. Increasing cases of malignant mesothelioma and the rising availability of treatment options for people suffering from this disease are key factors that are driving the market forward.

Which Region is Expected to Register Higher Growth Rate?

“Latin America is Anticipated to Exhibit Promising Growth Potential in the Upcoming Years”

According to recent market predictions, the Latin America market for malignant mesothelioma is expected to obtain a small share of 11.9% in 2024. The adoption rate for malignant mesothelioma therapeutics, however, is expected to witness intensified growth. Through 2034, this regional market is projected to record a 9.4% CAGR.

Rising prevalence of cancer and surging cognizance about present cancer treatment methods are anticipated to drive up the market demand. The development of advanced therapies is further expected to elevate the market’s scope.

Country-wise Insights

Which Country in North America Dominates the Regional Sphere?

“The United States is Forecast to Lead with a Share of 68.1% in North America”

The United States malignant mesothelioma market is estimated to attain US$ 141 million in 2024. With a projected CAGR of 6.4%, the market is forecast to attain a valuation of US$ 264 million by 2034.

The expansion of malignant mesothelioma industry in the United States is backed by an increasing count of leading players as well as rising spending on research and development. Additionally, significant investments in the healthcare sector and the availability of expert doctors are boosting medical tourism in the country. Thus surging the prospects for malignant mesothelioma industry players.

Which Country is Anticipated to Accelerate at a Promising Pace?

“Chile is Expected to Observe Flourishing Growth Rate”

Chile is expected to register a CAGR of 9.5% over the forecast period. The country is witnessing a significant rise in cases of malignant mesothelioma, which is creating a heightened demand for malignant mesothelioma therapeutics. Chile is expected to occupy a 65.3% share of Latin America in 2024. In the same year, the country is estimated to capture a market value of US$ 44 million.

Segment-wise Insights

Which Drug Type Captures a Considerable Market Share?

“Pemetrexed and Combination Gains a Leading Position in the Malignant Mesothelioma Market”

The pemetrexed and combination drug type enjoys a leading stance, occupying a share of 49.8% in 2024. Sales of pemetrexed and combination drugs are estimated to generate a revenue of US$ 280.0 million in 2024. Recording a purchase rate of 7.8% CAGR, pemetrexed and combination drugs are forecast to attain US$ 596.0 million by 2034. This segment’s growth hinges on the rising clinical trials by key players and related organizations to discover more effective pemetrexed and combination drugs.

Which Route of Administration is Highly Preferred?

“Parenteral Route of Administration is Substantially Preferred by Patients and Medical Professionals Alike”

The parenteral route of administration is expected to obtain a value share of 92.2% in 2024. Sales generated by this administration mode are estimated to be US$ 518.2 million in 2024. By 2034, the segment is forecast to attain US$ 1,075.7 million on the back of a 7.6% CAGR.

Increasing concerns over the full absorption of drugs and sufficient drug delivery to the tumor site are propelling the demand for the parenteral segment. This route of administration ensures a stronger therapeutic effect in comparison to oral medications.

Which Distribution Channel is Sought Frequently for Malignant Mesothelioma Medications?

“Individuals Prefer Purchasing Medications for Malignant Mesothelioma from Hospital Pharmacies”

The hospital pharmacy segment is expected to capture a dominant market share of 51.3% in 2024. The segment is estimated to be valued at US$ 288.4 million in 2024, and for 2034, it is forecast to reach US$ 618.4 million. In the meantime, the segment growth is projected to be 7.9% CAGR. Growing drug purchases for malignant mesothelioma from hospital pharmacies, due to their accessibility, is appreciating this segment’s value.

Competitive Landscape

Key players in the malignant mesothelioma market are investing in research and development activities for novel mesothelioma treatments, such as immunotherapy drugs, targeted therapies, and combination therapies, to provide significant benefits. Additionally, market leaders are optimizing their present drugs via formulations to reduce their side effects, improve their efficacy, and develop better delivery systems for effective differentiation.

Industry participants are creating and commercializing advanced diagnostic tools to detect malignant mesothelioma to enhance patient outcomes and market size. In tandem with this, players are charting new territories where the incidence rate for this disease is rising. Presently, markets in focus are Latin America and Asia Pacific, in addition to established markets.

Market contenders are also collaborating with patient advocacy groups, research institutions, and other healthcare providers to expand their reach, improve brand image, and increase research efficiency. Acquisitions and mergers with smaller or same-sized companies are also facilitating market consolidation.

Recent Developments in the Malignant Mesothelioma Market

• In June 2023, Amneal Pharmaceuticals, Inc. announced that it had received 505(b)(2) New Drug Application (NDA) permission from the United States FDA. This product is the first and single ready-to-use demonstration of pemetrexed for injection and requires no dilution, reconstitution, or refrigeration. This injectable is used to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer.
• In May 2023, researchers concluded that quinacrine, which is an antimalarial drug when applied to mesothelioma cells, can safeguard intense tumors from developing new blood vessels and causing cell death.
• In April 2023, the FDA presented fast-track designation to SynKIR-110, a novel T-Cell therapy, for the treatment of patients suffering from mesothelioma. It is an important milestone for the company as it acknowledges the efforts made by the firm to bring this life-saving drug to patients requiring new treatment options.
• In October 2020, the FDA granted permission to Opdivo (nivolumab) combined with Yervoy (ipilimumab) to treat mesothelioma. This drug combination is used as first-line treatment for adults suffering from malignant pleural mesothelioma. In 16 years, this is the first drug regimen which has been permitted for mesothelioma.

Segmentation of Malignant Mesothelioma Market Research

• By Drug Type:

  • Pemetrexed and combination
  • Cisplatin and combination
  • Carboplatin and combination
  • Gemcitabine and combination
  • Vinorelbine and combination
  • Others combinations

• By Route of Administration:

  • Oral
  • Parenteral

• By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia and Oceania
  • The Middle East and Africa